View Item 

Show simple item record

Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A
dc.contributor.authorSood, S. L.en_US
dc.contributor.authorCuker, A.en_US
dc.contributor.authorWang, C.en_US
dc.contributor.authorMetjian, A. D.en_US
dc.contributor.authorChiang, E. Y.en_US
dc.contributor.authorSoucie, J. M.en_US
dc.contributor.authorKonkle, B. A.en_US
dc.date.accessioned2013-06-18T18:32:38Z
dc.date.available2014-09-02T14:12:52Zen_US
dc.date.issued2013-07en_US
dc.identifier.citationSood, S. L.; Cuker, A.; Wang, C.; Metjian, A. D.; Chiang, E. Y.; Soucie, J. M.; Konkle, B. A. (2013). "Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A." Haemophilia 19(4): 595-601. <http://hdl.handle.net/2027.42/98234>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/98234
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherArthropathyen_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherJoint Range of Motionen_US
dc.subject.otherModerate Haemophilia Aen_US
dc.subject.otherVon Willebrand Factoren_US
dc.subject.otherVon Willebrand's Diseaseen_US
dc.titleSimilarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia Aen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23534856en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/98234/1/hae12119.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/98234/2/hae12119-sup-0001-AppendixS1.pdf
dc.identifier.doi10.1111/hae.12119en_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceLillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?. J Thromb Haemost 2009; 7 ( Suppl 1 ): 65 – 70.en_US
dc.identifier.citedreferenceWeiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390 – 404.en_US
dc.identifier.citedreferenceFederici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost 2006; 32: 555 – 65.en_US
dc.identifier.citedreferenceLak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236 – 9.en_US
dc.identifier.citedreferenceSumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment – results of a patient and Hemophilia Treatment Center Survey in the United States. Haemophilia 2004; 10: 360 – 6.en_US
dc.identifier.citedreferenceAhlberg A, Silwer J. Arthropathy in von Willebrand's disease. Acta Orthop Scand 1970; 41: 539 – 44.en_US
dc.identifier.citedreferenceVon Willebrand EA. Hereditary pseudohaemophilia. Haemophilia 1999; 5: 223 – 31 discussion 2.en_US
dc.identifier.citedreferenceSankarankutty M, Evans DI. Chronic arthropathy in von Willebrand's disease. Clin Lab Haematol 1983; 5: 149 – 56.en_US
dc.identifier.citedreferenceAbshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res 2006; 118 ( Suppl 1 ): S3 – 7.en_US
dc.identifier.citedreferenceSoucie JM, Forsyth A, Watson C, Wang C, U.D.C. Investigators. Joint Range of Motion (ROM) measurements in patients with von Willebrand disease compared with normal subjects. J Thromb Heamost 2007; 5 ( Suppl. 2 ): P‐W‐188.en_US
dc.identifier.citedreferenceMetjian AD, Wang C, Sood SL et al. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia 2009; 15: 918 – 25.en_US
dc.identifier.citedreferenceSoucie JM, Cianfrini C, Janco RL et al. Joint range‐of‐motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467 – 73.en_US
dc.identifier.citedreferenceFischer K, van der Bom JG, Mauser‐Bunschoten EP et al. Endogenous clotting factor activity and long‐term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84: 977 – 80.en_US
dc.identifier.citedreferenceSoucie JM, Wang C, Forsyth A et al. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17: 500 – 7.en_US
dc.identifier.citedreferenceBrinkmann T, Kahnert H, Prohaska W, Nordfang O, Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994; 32: 313 – 7.en_US
dc.identifier.citedreferenceBerckmans RJ, Nieuwland R, Tak PP et al. Cell‐derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII‐dependent mechanism. Arthritis Rheum 2002; 46: 2857 – 66.en_US
dc.identifier.citedreferenceValentino LA, Hakobyan N, Enockson C. Blood‐induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45: S50 – 7.en_US
dc.identifier.citedreferenceBerntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621 – 5.en_US
dc.identifier.citedreferenceBerntorp E, Petrini P. Long‐term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 ( Suppl 1 ): S23 – 6.en_US
dc.identifier.citedreferenceBerntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14 ( Suppl 5 ): 47 – 53.en_US
dc.identifier.citedreferenceFederici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 2008; 6 ( Suppl 2 ): s26 – 32.en_US
dc.identifier.citedreferenceFederici AB, Gianniello F, Canciani MT, Mannucci PM Secondary long‐term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study. ASH Annual Meeting Abstracts 2005; 106: 1782.en_US
dc.identifier.citedreferenceHalimeh S, Krumpel A, Rott H et al. Long‐term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost 2011; 105: 597 – 604.en_US
dc.identifier.citedreferenceBerntorp E, Abshire T. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept. Thromb Res 2006; 118 ( Suppl 1 ): S19 – 22.en_US
dc.identifier.citedreferenceAbshire TC, Federici AB, Alvarez MT et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76 – 81.en_US
dc.identifier.citedreferenceSadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103 – 14.en_US
dc.identifier.citedreferenceNichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia 2008; 14: 171 – 232.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae12119.pdf
Size:
229.5KB
Format:
PDF
View/Open
Name:
hae12119-sup-0001-AppendixS1.pdf
Size:
82.88KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.